| Vol. 6.39 – 9 October, 2020 |
| |
|
|
| By combining quantitative imaging with RNA sequencing, scientists showed the role of endogenous retinoic acid metabolism in initiating transcriptional programs that guide the cell-fate transitions of intestinal epithelium, and identified an inhibitor of the retinoid X receptor that improves intestinal regeneration in vivo. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors report the creation of a uniquely acting HSP70 inhibitor that targets multiple compartments in the cancer cell including mitochondria. [Cancer Research] |
|
|
|
| Bioinformatics binding site analysis, Luciferase reporter assay, Ago2 immunoprecipitation assays, RNA pull-down assay, RT-qPCR and Western blotting were utilized to demonstrate that mechanism of RP11-757G1.5 acts as a molecular sponge of miR-139-5p to regulate the expression of YAP1. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| In vitro and in vivo functional analyses showed that B7-H3 enhanced resistance against irradiation in colorectal cancer cells by upregulating KIF15 expression via NF-κB, which activated ERK1/2 signaling, a key pathway involved in radioresistance in cancers. [Cell Death & Disease] |
|
|
|
| Two flavonols, galangin and kaempferol, were heated at 100°C for 30 min prior to assessing their effects on barrier function of rat intestinal epithelial cells. [Journal of Nutritional Biochemistry] |
|
|
|
| Bile acid‐activated farnesoid X receptor enhanced glucose uptake in intestinal epithelial cells by increasing the expression of glucose transporter 2, which depended on ERK1/2 phosphorylation via S1PR2. However, it also reduced the cell energy generation via inhibition of oxidative phosphorylation, which was crucial for intestinal glucose transport. [Journal of Cellular and Molecular Medicine] |
|
|
|
| The authors suggest differential ability of specific human milk oligosaccharides (HMOs) in modulating the intestinal barrier and supporting the potential of supplementation with combinations of available HMOs to promote gut health and protect against intestinal inflammatory disorders. [Nutrients] |
|
|
|
| Using pharmacological and genetic perturbations in cultured intestinal epithelial cells, investigators found that non-muscle myosin-2C controlled the length of growing microvilli by regulating actin turnover in a manner that required a fully active motor domain. [Molecular Biology of the Cell] |
|
|
|
| The anti-proliferative effects of six derivatives of oxyepiberberine on colon cancer cells were assessed. Among six derivatives, oxyepiberberine showed the greatest anti-proliferative effect on LS-1034 cells. [Investigational New Drugs] |
|
|
|
|
| The authors present the current status of in vitro / ex vivo 3D models of human gastric cancer as a surrogate to in vivo tumors. [Cancers] |
|
|
|
|
| FDA regulatory acceptance enabled a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities. [Seed Health (PR Newswire Inc.)] |
|
|
|
|
| January 9 – January 12, 2021 Lake Buena Vista, Florida, United States |
|
|
|
|
|
| Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| Moffitt Cancer Center – Tempa, Florida, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Chr. Hansen A/S – Hørsholm, Denmark |
|
|
|
| City of Hope – Monrovia, California, United States |
|
|
|
|